JP2023071900A5 - - Google Patents

Download PDF

Info

Publication number
JP2023071900A5
JP2023071900A5 JP2023034164A JP2023034164A JP2023071900A5 JP 2023071900 A5 JP2023071900 A5 JP 2023071900A5 JP 2023034164 A JP2023034164 A JP 2023034164A JP 2023034164 A JP2023034164 A JP 2023034164A JP 2023071900 A5 JP2023071900 A5 JP 2023071900A5
Authority
JP
Japan
Prior art keywords
composition
disorder
depression
day
mirtazapine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023034164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023071900A (ja
JP7585369B2 (ja
Filing date
Publication date
Priority claimed from PCT/IL2018/050570 external-priority patent/WO2018216020A1/en
Application filed filed Critical
Publication of JP2023071900A publication Critical patent/JP2023071900A/ja
Publication of JP2023071900A5 publication Critical patent/JP2023071900A5/ja
Application granted granted Critical
Publication of JP7585369B2 publication Critical patent/JP7585369B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023034164A 2017-05-25 2023-03-07 Nmdarアンタゴニスト-応答性精神神経障害のための併用療法 Active JP7585369B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762510801P 2017-05-25 2017-05-25
US62/510,801 2017-05-25
US201762518020P 2017-06-12 2017-06-12
US62/518,020 2017-06-12
PCT/IL2018/050570 WO2018216020A1 (en) 2017-05-25 2018-05-24 Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders
JP2019564867A JP7308761B2 (ja) 2017-05-25 2018-05-24 Nmdarアンタゴニスト-応答性精神神経障害のための併用療法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019564867A Division JP7308761B2 (ja) 2017-05-25 2018-05-24 Nmdarアンタゴニスト-応答性精神神経障害のための併用療法

Publications (3)

Publication Number Publication Date
JP2023071900A JP2023071900A (ja) 2023-05-23
JP2023071900A5 true JP2023071900A5 (cg-RX-API-DMAC7.html) 2023-06-20
JP7585369B2 JP7585369B2 (ja) 2024-11-18

Family

ID=64396350

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019564988A Active JP7312116B2 (ja) 2017-05-25 2018-05-24 外傷後ストレス障害の治療用の製剤
JP2019564867A Active JP7308761B2 (ja) 2017-05-25 2018-05-24 Nmdarアンタゴニスト-応答性精神神経障害のための併用療法
JP2023034164A Active JP7585369B2 (ja) 2017-05-25 2023-03-07 Nmdarアンタゴニスト-応答性精神神経障害のための併用療法
JP2023077666A Active JP7537675B2 (ja) 2017-05-25 2023-05-10 外傷後ストレス障害の治療用の製剤

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2019564988A Active JP7312116B2 (ja) 2017-05-25 2018-05-24 外傷後ストレス障害の治療用の製剤
JP2019564867A Active JP7308761B2 (ja) 2017-05-25 2018-05-24 Nmdarアンタゴニスト-応答性精神神経障害のための併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023077666A Active JP7537675B2 (ja) 2017-05-25 2023-05-10 外傷後ストレス障害の治療用の製剤

Country Status (13)

Country Link
US (4) US20180338956A1 (cg-RX-API-DMAC7.html)
EP (2) EP3630103B1 (cg-RX-API-DMAC7.html)
JP (4) JP7312116B2 (cg-RX-API-DMAC7.html)
KR (2) KR102608479B1 (cg-RX-API-DMAC7.html)
CN (2) CN110996946A (cg-RX-API-DMAC7.html)
AU (2) AU2018274767A1 (cg-RX-API-DMAC7.html)
BR (2) BR112019024817A2 (cg-RX-API-DMAC7.html)
CA (2) CA3064846A1 (cg-RX-API-DMAC7.html)
IL (2) IL270916B2 (cg-RX-API-DMAC7.html)
MX (2) MX394875B (cg-RX-API-DMAC7.html)
RU (2) RU2019143573A (cg-RX-API-DMAC7.html)
WO (2) WO2018216020A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201908617B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
KR102608479B1 (ko) * 2017-05-25 2023-12-01 글리테크 엘엘씨. Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
WO2019160057A1 (ja) 2018-02-15 2019-08-22 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
CN118121577A (zh) 2018-05-04 2024-06-04 感知神经科学公司 治疗物质滥用的方法
US20210386689A1 (en) * 2018-10-31 2021-12-16 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders
US12637411B2 (en) 2019-01-30 2026-05-26 Mggm Llc Structurally modified opioids for prevention and treatment of diseases and conditions
KR20220045929A (ko) * 2019-04-09 2022-04-13 비스타젠 쎄라퓨틱스, 인크. 신경 질환의 치료 반응과 관련된 유전적 변이
JP7869138B2 (ja) * 2020-01-03 2026-06-02 ユニバーシティ オブ パドヴァ 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン
CN115677519A (zh) * 2021-07-22 2023-02-03 立科时代(武汉)生物科技有限公司 L-4-溴-犬尿氨酸及其在制备治疗抑郁症药物中的应用
CN113648320A (zh) * 2021-08-16 2021-11-16 中国人民解放军军事科学院军事医学研究院 赛洛西宾抗创伤后应激障碍的医药用途
EP4709379A1 (en) * 2023-06-29 2026-03-18 The Sarah Herzog Memorial Hospital-Ezrath Nashim Nmdar antagonist for the treatment of inflammatory diseases in patients with depression comorbidity
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
AU765603C (en) 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
WO2005016319A2 (en) * 2003-08-06 2005-02-24 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20050096396A1 (en) * 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
ATE407117T1 (de) 2003-01-16 2008-09-15 Acadia Pharm Inc Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
WO2005079756A2 (en) 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
CN101031548B (zh) 2004-09-27 2011-04-06 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备
TW200631584A (en) 2004-11-15 2006-09-16 Akzo Nobel Nv A medicament related to mirtazapine for the treatment of hot flush
US8450336B2 (en) 2006-12-14 2013-05-28 Nps Pharmaceuticals, Inc Use of D-serine derivatives for the treatment of anxiety disorders
US20100216805A1 (en) * 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9789093B2 (en) * 2011-01-31 2017-10-17 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
EP2841063A2 (en) 2012-04-27 2015-03-04 Indiana University Research and Technology Corporation Compositions and methods for treating ptsd and related diseases
US9949983B2 (en) * 2013-10-18 2018-04-24 Psyadon Pharmaceuticals, Inc. Fused benzazepines for treatment of stuttering
US20180271869A1 (en) 2014-09-22 2018-09-27 Jie Liu Treatment of anxiety disorders and autism spectrum disorders
WO2016061320A2 (en) * 2014-10-15 2016-04-21 Rowan University Timber therapy for post-traumatic stress disorder
AU2016303610A1 (en) 2015-08-04 2018-02-01 Confluence Pharmaceuticals, Llc Combination therapy using acamprosate and D-cycloserine
WO2017160813A1 (en) * 2016-03-15 2017-09-21 University Of The Sciences Compositions and methods for treating compulsive-like behavior in a subject
KR102608479B1 (ko) * 2017-05-25 2023-12-01 글리테크 엘엘씨. Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법

Similar Documents

Publication Publication Date Title
RU2019143573A (ru) Комбинированная терапия нейропсихиатрических расстройств, восприимчивых к антагонисту nmdar
Joffe et al. Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine
JP2011157378A5 (cg-RX-API-DMAC7.html)
JP2013504577A5 (cg-RX-API-DMAC7.html)
CA2549467A1 (en) A preventive agent for vasculitis
JP2007513073A5 (cg-RX-API-DMAC7.html)
CN103732252B (zh) 使用抗cd‑19抗体和氮芥的联合治疗
JP2016538270A5 (cg-RX-API-DMAC7.html)
Louis et al. Severe asthma standard-of-care background medication reduction with benralizumab: ANDHI in practice substudy
JP2010500370A5 (cg-RX-API-DMAC7.html)
Kupryś-Lipińska et al. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma
JP2015524816A5 (cg-RX-API-DMAC7.html)
RU2010132178A (ru) Агенты, уменьшающие количество в-клеток, такие как антитела против cd20 или их фрагменты, для лечения синдрома хронической усталости
Peters et al. Treatment of premenstrual breakthrough of depression with adjunctive oral contraceptive pills compared with placebo
WO2020119424A1 (zh) 一种含有sumo抑制剂的组合物及应用
EP3512514A1 (en) Novel regimes of fxr agonists
Jiang et al. The N-methyl-d-aspartate receptor hypothesis of ketamine’s antidepressant action: Evidence and controversies
Zhu et al. Protective effects of Huang Qi Huai granules on adriamycin nephrosis in rats
Rousseau et al. Acute kidney injury after CAR-T cell infusion
Alderuccio et al. Limited duration loncastuximab tesirine with rituximab induces high complete metabolic response rate in high-risk relapsed/refractory follicular lymphoma-a phase 2 study
Kennedy Agomelatine: efficacy at each phase of antidepressant treatment
CN101068549A (zh) 与5-fu和5-fu前药组合施用dpd抑制剂的方法
JP2024519545A5 (cg-RX-API-DMAC7.html)
Tan et al. Comparative effectiveness and safety for the treatments despite optimized renin-angiotensin system blockade among IgA nephropathy patients at high-risk of disease progression: A network meta-analysis of randomized controlled trials
Takahashi et al. α7 Nicotinic acetylcholine receptor stimulation inhibits lipopolysaccharide-induced interleukin-18 and-12 production in monocytes